Kenneth Kelley of PaxVax in the U.S. seeks to develop a low-cost, single-dose, oral polio vaccine using a live, safe adenovirus containing protein-encoding genes from poliovirus. If successful, this vaccine can be used to eradicate polio while eliminating the risks of vaccine-derived polio disease and poliovirus re-introduction.
Grant ID
OPP1036194
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Challenge
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False